xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06028399</url>
    </required_header>
    <id_info>
      <org_study_id>7170523HSPAT</org_study_id>
      <nct_id>NCT06028399</nct_id>
    </id_info>
    <brief_title>Concurrent Training on Patients With Type-II DM Associated PAD.</brief_title>
    <official_title>Effects of Concurrent Training on Glycaemic &amp; Vascular Parameters Among Patients With Type-II DM Associated Peripheral Artery Disease.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Ziauddin University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Ziauddin University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This clinical trial aims to analyze the effects of concurrent vs aerobic training on glycemic&#xD;
        control, ABI, functional capacity and disease-specific QOL among patients with Type-II&#xD;
        DM-associated PAD at baseline &amp; after 12 weeks of intervention. The main questions it aims to&#xD;
        answer are:&#xD;
  &#xD;
          1. Is concurrent training more effective than aerobic training in improving glycemic&#xD;
             control among patients with Type-II DM-associated PAD?&#xD;
  &#xD;
          2. Is concurrent training more effective than aerobic training in improving ABI among&#xD;
             patients with Type-II DM-associated PAD?&#xD;
  &#xD;
          3. Is concurrent training more effective than aerobic training in enhancing functional&#xD;
             capacity among patients with Type-II DM-associated PAD?&#xD;
  &#xD;
          4. Is concurrent training more effective than aerobic training in improving QOL among&#xD;
             patients with Type-II DM-associated PAD? Signed informed consent will be taken before&#xD;
             participation. For exercise training, Both will perform Warm up for 10 - 12 minutes,&#xD;
             followed by 30 - 60 minutes of training protocol and then Cool down exercises for 10 -&#xD;
             12 minutes. Group A will perform concurrent training, whereas Group B will perform&#xD;
             aerobic training.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        DATA COLLECTION PROCEDURE;&#xD;
  &#xD;
        Eighty patients will be referred from the OPD of Dr. Ziauddin Hospital Karachi, Pakistan.&#xD;
        Signed informed consent will be obtained before participation. In the screening session, PAD&#xD;
        by Fontaine's stage IIa, ABI (&lt;0.9), and an international Physical activity questionnaire&#xD;
        (IPAQ) to assess sedentary behaviour will be collected. For IPAQ interpretation, &lt;600 MET&#xD;
        Minutes will be considered category 1 (Lowest level of physical activity). In the next&#xD;
        session, baseline measurements of all participants will be collected and documented,&#xD;
        including HbA1C, ABI at rest, Functional Capacity, and QOL.&#xD;
  &#xD;
        Moreover, Target heart rate (THR) and 1RM will be calculated for appropriate exercise&#xD;
        intensity and BMI. Further, All patients will be randomly allocated into two groups. Group A&#xD;
        (n=40) will perform concurrent training, whereas Group B will perform aerobic training&#xD;
        (n=40). All patients will receive a brief explanation and demonstration of the exercise&#xD;
        session during the familiarisation. Patients will perform 3 sessions weekly to improve their&#xD;
        capability to do exercises and develop the exercise capacity needed to begin at the intensity&#xD;
        of their allocated training protocol. Both groups will perform warm-up exercises for 10 - 12&#xD;
        minutes during the training session, followed by training protocol and then cool-down&#xD;
        exercises for 10 - 12 minutes. Group A will perform concurrent training for 30 to 60 minutes,&#xD;
        whereas Group B will perform aerobic training for 30 - 60 minutes. Both groups will perform&#xD;
        warm-up and cool-down exercises for 10 - 12 minutes, including 5 minutes of static cycling&#xD;
        followed by 5 reps. of static stretching of the hamstring, quadriceps, and calf muscles on&#xD;
        each limb with the 10-second hold of each stretch (ACSM, 2018). During the intervention&#xD;
        period, patients will be assessed for Heart rate, blood pressure, and random blood sugar&#xD;
        before and after each session for 12 weeks duration, and perceived exertion status will be&#xD;
        used during exercise for analyzing the exercise intensity.&#xD;
  &#xD;
        Group A (Concurrent Training):&#xD;
  &#xD;
        Concurrent training combines aerobic and resistance training within the same session.&#xD;
        Patients in this group will perform aerobic exercises and resistance training for 30 - 60&#xD;
        minutes, comprising 3 sessions per week for 12 weeks under the supervision of a physical&#xD;
        therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR&#xD;
        for 15 - 40 minutes, followed by resistance training using an elastic resistance band at 60 -&#xD;
        80% of 1 RM, following appropriate rest intervals. The patient will perform lower limb&#xD;
        resistance exercises, including Quadriceps extension, leg curls, calf raises &amp; toe raises.&#xD;
  &#xD;
        Group B (Aerobic Training):&#xD;
  &#xD;
        Patients in this group will perform aerobic exercise for 12 weeks. All Patients will be&#xD;
        assessed for HR, BP and RBS before and after each session. Patients in this group will&#xD;
        perform aerobic exercises for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks&#xD;
        under the supervision of a physical therapist. Aerobic training will be performed on a&#xD;
        treadmill at an intensity of 40 - 60 % THR.&#xD;
  &#xD;
        After 12 weeks of intervention, all patients will be assessed for HbA1C, ABI, functional&#xD;
        capacity, and QOL and documented for further data analysis.&#xD;
  &#xD;
        SPECIAL CONSIDERATION FOR EXERCISE&#xD;
  &#xD;
          -  Educate the patient about the signs and symptoms of hypoglycemia.&#xD;
  &#xD;
          -  Hypoglycemia manifestations (particularly tachycardia) may mask due to Β-Blockers.&#xD;
  &#xD;
          -  Blood glucose level monitoring (before and after exercise).&#xD;
  &#xD;
          -  Carbohydrate intake (up to 15 g before exercise participation) to prevent hypoglycemia&#xD;
             *when starting RBS ≤100 mg/dL.&#xD;
  &#xD;
          -  Avoid head-down activities and the Valsalva manoeuvre.&#xD;
  &#xD;
          -  For peripheral neuropathy, closely examine feet regularly to detect sores or ulcers and&#xD;
             incorporate proper foot care (dry feet, silica gel or air midsoles &amp; polyester socks).&#xD;
  &#xD;
        EXERCISE TERMINATION CRITERIA The exercise will be terminated if the patient reports any&#xD;
        following symptoms during exercise.&#xD;
  &#xD;
          -  The onset of Chest pain&#xD;
  &#xD;
          -  Shortness of breath (Borg's scale &gt;15)&#xD;
  &#xD;
          -  Hemodynamic imbalance during exercise is caused by limited perfusion (Pale appearance,&#xD;
             cool skin, Diaphoresis (sweating), Physical exertion, altered pulse) and Low blood&#xD;
             pressure (very late sign)&#xD;
  &#xD;
          -  On the patient's request to stop exercise&#xD;
  &#xD;
          -  Ischemic limb pain that is not alleviated after 10 minutes&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Enrolling by invitation</overall_status>
    <start_date type="Actual">July 15, 2023</start_date>
    <completion_date type="Anticipated">November 2023</completion_date>
    <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>In this randomized controlled trial, there are 2 parallel groups. Group A for Concurrent training and Group B for Aerobic training.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Double (Participant, Outcomes Assessor)</masking>
      <masking_description>Participants will be allocated to the intervention group by using sealed envelop methods of simple random sampling. They were masked for the treatment allocation group. For assessment of outcome measures, HbA1C will be assessed by lab investigator, ABI and Functioncal capacity will be assessed by the physiotherapist who will be supervised the session.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>HbA1c for glycemic control</measure>
      <time_frame>12 weeks</time_frame>
      <description>The hemoglobin A1C (HbA1c) is a gold standard for assessing glycemic control for 2-3 months (Chehregosha et al., 2019). HbA1C has excellent reliability and validity (Sn= 0.8, Sp=0.9, AUROC = 0.9) (Rathod et al., 2018).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Ankle Brachial Index (ABI) for peripheral artery disease</measure>
      <time_frame>12 weeks</time_frame>
      <description>ABI is a non-invasive method for determining the presence and severity of PAD, commonly used in clinical settings (Thurston and Dawson, 2019). Doppler ABI has 80.3% sensitivity and 78.1% specificity on the side with high pressures (Mayr et al., 2019). An ABI of 0.9 is considered diagnostic for PAD. Using a portable Doppler Ultrasound with a 5MHz probe, the systolic pressures of the right and left brachial, &amp; dorsalis pedis arteries will be assessed then higher systolic blood pressure will be considered for the study. The ABI will be calculated by dividing the brachial pressures by the lower extremity (Chen et al., 2021).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Functional Capacity for functional claudication distance</measure>
      <time_frame>12 weeks</time_frame>
      <description>The patient will walk on 100 feet indoor track, and distance will be measured on claudication symptoms when the patient prefers to stop walking, which will analyze pre and post-intervention to assess the effectiveness of therapeutic intervention (Sinnige et al., 2022). The reliability of FCD is 0.959. FCD is a reliable and valid measurement for determining functional capacity in patients with intermittent claudication (Bubb et al., 2021, Abola et al., 2020).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Quality of life for disease-specific patient reported outcomes</measure>
      <time_frame>12 weeks</time_frame>
      <description>The Vasculo-6 questionnaire evaluates disease-specific QOL among patients with symptomatic PAD. Each question is scored out of four, of which one is the lowest score, and four will be the highest. The sum of all components yields the final score. The final score could range between 6-24 points. VQ-6 has strong reliability (Cronbach=0.82), validity (AUC=0.754) &amp; excellent receptivity to change after intervention (standard response means=1.12)</description>
    </primary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">80</enrollment>
    <condition>Type 2 Diabetes With Peripheral Angiopathy</condition>
    <arm_group>
      <arm_group_label>Concurrent Training</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Concurrent training combines aerobic and resistance training within the same session for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Aerobic Training</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Aerobic training for 30 - 60 minutes comprises 3 sessions per week for 12 weeks.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Concurrent Training</intervention_name>
      <description>The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise &amp; toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.</description>
      <arm_group_label>Concurrent Training</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Aerobic Training</intervention_name>
      <description>The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.</description>
      <arm_group_label>Aerobic Training</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age: 40 - 50 years&#xD;
  &#xD;
            -  Type-II DM&#xD;
  &#xD;
            -  Duration of DM: &gt; 10 years&#xD;
  &#xD;
            -  Baseline HbA1C (&gt; 6.6%)&#xD;
  &#xD;
            -  Intermittent claudication corresponding to Fontaine Stage IIa&#xD;
  &#xD;
            -  PAD by an ABI scale; &lt; 0.9 at rest&#xD;
  &#xD;
            -  Had &lt; 160 mmHg SBP and &lt; 105 mmHg DBP&#xD;
  &#xD;
            -  Sedentary lifestyle by IPAQ-SF&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Smokers&#xD;
  &#xD;
            -  Insulin dependent individuals&#xD;
  &#xD;
            -  Patients with Complicated cardiovascular disease that might limit their ability to -&#xD;
               participate in the intervention period physically (e.g. unstable cardiopulmonary&#xD;
               symptoms, ischemic heart failure, or chronic kidney disease) and cancer&#xD;
  &#xD;
            -  Any major surgery or revascularization procedure within the previous 1 year&#xD;
  &#xD;
            -  In case of a history of severe arthritis that may limit exercise performance&#xD;
  &#xD;
            -  Diabetic foot (ulceration or gangrene)&#xD;
  &#xD;
            -  Patients with stroke&#xD;
  &#xD;
            -  BMI = &gt;30 classified by WHO-Asian as obesity class II&#xD;
  &#xD;
            -  Unable to follow the intervention protocol or visit three times per week for exercise&#xD;
  &#xD;
            -  Participation in any clinical trial during the past six months&#xD;
  &#xD;
            -  Revocation to consent&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>40 Years</minimum_age>
      <maximum_age>50 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Uroosa Amin, DPT</last_name>
      <role>Principal Investigator</role>
      <affiliation>Ziauddin University</affiliation>
    </overall_official>
    <location>
      <facility>
        <name>Uroosa Amin</name>
        <address>
          <city>Karachi</city>
          <state>Sindh</state>
          <zip>74700</zip>
          <country>Pakistan</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Pakistan</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 30, 2023</study_first_submitted>
    <study_first_submitted_qc>September 7, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 8, 2023</study_first_posted>
    <last_update_submitted>September 7, 2023</last_update_submitted>
    <last_update_submitted_qc>September 7, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Ziauddin University</investigator_affiliation>
      <investigator_full_name>Uroosa Amin</investigator_full_name>
      <investigator_title>Student</investigator_title>
    </responsible_party>
    <keyword>Concurrent Exercise Training</keyword>
    <keyword>Physical Exercise</keyword>
    <keyword>Glycated hemoglobin</keyword>
    <keyword>Glycemic control</keyword>
    <keyword>Insulin Resistance</keyword>
    <keyword>Type 2 Diabetes Mellitus</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Peripheral Vascular Diseases</mesh_term>
      <mesh_term>Peripheral Arterial Disease</mesh_term>
      <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06028399
  org study id: 7170523HSPAT
  nct id: NCT06028399
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This clinical trial aims to analyze the effects of concurrent vs aerobic training on glycemic
        control, ABI, functional capacity and disease-specific QOL among patients with Type-II
        DM-associated PAD at baseline & after 12 weeks of intervention. The main questions it aims to
        answer are:
  
          1. Is concurrent training more effective than aerobic training in improving glycemic
             control among patients with Type-II DM-associated PAD?
  
          2. Is concurrent training more effective than aerobic training in improving ABI among
             patients with Type-II DM-associated PAD?
  
          3. Is concurrent training more effective than aerobic training in enhancing functional
             capacity among patients with Type-II DM-associated PAD?
  
          4. Is concurrent training more effective than aerobic training in improving QOL among
             patients with Type-II DM-associated PAD? Signed informed consent will be taken before
             participation. For exercise training, Both will perform Warm up for 10 - 12 minutes,
             followed by 30 - 60 minutes of training protocol and then Cool down exercises for 10 -
             12 minutes. Group A will perform concurrent training, whereas Group B will perform
             aerobic training.
  DATA COLLECTION PROCEDURE;
  
        Eighty patients will be referred from the OPD of Dr. Ziauddin Hospital Karachi, Pakistan.
        Signed informed consent will be obtained before participation. In the screening session, PAD
        by Fontaine's stage IIa, ABI (<0.9), and an international Physical activity questionnaire
        (IPAQ) to assess sedentary behaviour will be collected. For IPAQ interpretation, <600 MET
        Minutes will be considered category 1 (Lowest level of physical activity). In the next
        session, baseline measurements of all participants will be collected and documented,
        including HbA1C, ABI at rest, Functional Capacity, and QOL.
  
        Moreover, Target heart rate (THR) and 1RM will be calculated for appropriate exercise
        intensity and BMI. Further, All patients will be randomly allocated into two groups. Group A
        (n=40) will perform concurrent training, whereas Group B will perform aerobic training
        (n=40). All patients will receive a brief explanation and demonstration of the exercise
        session during the familiarisation. Patients will perform 3 sessions weekly to improve their
        capability to do exercises and develop the exercise capacity needed to begin at the intensity
        of their allocated training protocol. Both groups will perform warm-up exercises for 10 - 12
        minutes during the training session, followed by training protocol and then cool-down
        exercises for 10 - 12 minutes. Group A will perform concurrent training for 30 to 60 minutes,
        whereas Group B will perform aerobic training for 30 - 60 minutes. Both groups will perform
        warm-up and cool-down exercises for 10 - 12 minutes, including 5 minutes of static cycling
        followed by 5 reps. of static stretching of the hamstring, quadriceps, and calf muscles on
        each limb with the 10-second hold of each stretch (ACSM, 2018). During the intervention
        period, patients will be assessed for Heart rate, blood pressure, and random blood sugar
        before and after each session for 12 weeks duration, and perceived exertion status will be
        used during exercise for analyzing the exercise intensity.
  
        Group A (Concurrent Training):
  
        Concurrent training combines aerobic and resistance training within the same session.
        Patients in this group will perform aerobic exercises and resistance training for 30 - 60
        minutes, comprising 3 sessions per week for 12 weeks under the supervision of a physical
        therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR
        for 15 - 40 minutes, followed by resistance training using an elastic resistance band at 60 -
        80% of 1 RM, following appropriate rest intervals. The patient will perform lower limb
        resistance exercises, including Quadriceps extension, leg curls, calf raises & toe raises.
  
        Group B (Aerobic Training):
  
        Patients in this group will perform aerobic exercise for 12 weeks. All Patients will be
        assessed for HR, BP and RBS before and after each session. Patients in this group will
        perform aerobic exercises for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks
        under the supervision of a physical therapist. Aerobic training will be performed on a
        treadmill at an intensity of 40 - 60 % THR.
  
        After 12 weeks of intervention, all patients will be assessed for HbA1C, ABI, functional
        capacity, and QOL and documented for further data analysis.
  
        SPECIAL CONSIDERATION FOR EXERCISE
  
          -  Educate the patient about the signs and symptoms of hypoglycemia.
  
          -  Hypoglycemia manifestations (particularly tachycardia) may mask due to Β-Blockers.
  
          -  Blood glucose level monitoring (before and after exercise).
  
          -  Carbohydrate intake (up to 15 g before exercise participation) to prevent hypoglycemia
             *when starting RBS ≤100 mg/dL.
  
          -  Avoid head-down activities and the Valsalva manoeuvre.
  
          -  For peripheral neuropathy, closely examine feet regularly to detect sores or ulcers and
             incorporate proper foot care (dry feet, silica gel or air midsoles & polyester socks).
  
        EXERCISE TERMINATION CRITERIA The exercise will be terminated if the patient reports any
        following symptoms during exercise.
  
          -  The onset of Chest pain
  
          -  Shortness of breath (Borg's scale >15)
  
          -  Hemodynamic imbalance during exercise is caused by limited perfusion (Pale appearance,
             cool skin, Diaphoresis (sweating), Physical exertion, altered pulse) and Low blood
             pressure (very late sign)
  
          -  On the patient's request to stop exercise
  
          -  Ischemic limb pain that is not alleviated after 10 minutes
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: In this randomized controlled trial, there are 2 parallel groups. Group A for Concurrent training and Group B for Aerobic training.
  primary purpose: Treatment
  masking: Double (Participant, Outcomes Assessor)
  masking description: Participants will be allocated to the intervention group by using sealed envelop methods of simple random sampling. They were masked for the treatment allocation group. For assessment of outcome measures, HbA1C will be assessed by lab investigator, ABI and Functioncal capacity will be assessed by the physiotherapist who will be supervised the session.
  measure: HbA1c for glycemic control
  time frame: 12 weeks
  description: The hemoglobin A1C (HbA1c) is a gold standard for assessing glycemic control for 2-3 months (Chehregosha et al., 2019). HbA1C has excellent reliability and validity (Sn= 0.8, Sp=0.9, AUROC = 0.9) (Rathod et al., 2018).
  measure: Ankle Brachial Index (ABI) for peripheral artery disease
  time frame: 12 weeks
  description: ABI is a non-invasive method for determining the presence and severity of PAD, commonly used in clinical settings (Thurston and Dawson, 2019). Doppler ABI has 80.3% sensitivity and 78.1% specificity on the side with high pressures (Mayr et al., 2019). An ABI of 0.9 is considered diagnostic for PAD. Using a portable Doppler Ultrasound with a 5MHz probe, the systolic pressures of the right and left brachial, & dorsalis pedis arteries will be assessed then higher systolic blood pressure will be considered for the study. The ABI will be calculated by dividing the brachial pressures by the lower extremity (Chen et al., 2021).
  measure: Functional Capacity for functional claudication distance
  time frame: 12 weeks
  description: The patient will walk on 100 feet indoor track, and distance will be measured on claudication symptoms when the patient prefers to stop walking, which will analyze pre and post-intervention to assess the effectiveness of therapeutic intervention (Sinnige et al., 2022). The reliability of FCD is 0.959. FCD is a reliable and valid measurement for determining functional capacity in patients with intermittent claudication (Bubb et al., 2021, Abola et al., 2020).
  measure: Quality of life for disease-specific patient reported outcomes
  time frame: 12 weeks
  description: The Vasculo-6 questionnaire evaluates disease-specific QOL among patients with symptomatic PAD. Each question is scored out of four, of which one is the lowest score, and four will be the highest. The sum of all components yields the final score. The final score could range between 6-24 points. VQ-6 has strong reliability (Cronbach=0.82), validity (AUC=0.754) & excellent receptivity to change after intervention (standard response means=1.12)
  arm group label: Concurrent Training
  arm group type: Experimental
  description: Concurrent training combines aerobic and resistance training within the same session for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks.
  arm group label: Aerobic Training
  arm group type: Active Comparator
  description: Aerobic training for 30 - 60 minutes comprises 3 sessions per week for 12 weeks.
  intervention type: Other
  intervention name: Concurrent Training
  description: The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise & toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
  arm group label: Concurrent Training
  intervention type: Other
  intervention name: Aerobic Training
  description: The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
  arm group label: Aerobic Training
  criteria: 
  gender: All
  minimum age: 40 Years
  maximum age: 50 Years
  healthy volunteers: No
  last name: Uroosa Amin, DPT
  role: Principal Investigator
  affiliation: Ziauddin University
  facility: 
  country: Pakistan
  responsible party type: Principal Investigator
  investigator affiliation: Ziauddin University
  investigator full name: Uroosa Amin
  investigator title: Student
  mesh term: Peripheral Vascular Diseases
  mesh term: Peripheral Arterial Disease
  mesh term: Diabetes Mellitus, Type 2
  sharing ipd: No